SLC2A1 and cancer: 60 of 151 cancers (39.7%) had high expression (cut-off value: 8) of HIF-1α, 42 of 152 cancers (27.6%) had high expression (cut-off value: 8) of c-Met, 45 of 144 cancers (31.3%) had increased expression (cut-off value: 2) of CA9, 37 of 162 (22.8%) had elevated expression (cut-off value: 8) of GLUT1.